MyAmyloidosisTeam

Amvuttra (vutrisiran) is an FDA-approved medication for treating hereditary ATTR (hATTR) amyloidosis. It works by blocking the TTR gene from making amyloid protein, which helps prevent further buildup of amyloid in the body.

This medication is specifically approved for treating both nerve involvement (polyneuropathy) and Show Full Answer

Amvuttra (vutrisiran) is an FDA-approved medication for treating hereditary ATTR (hATTR) amyloidosis. It works by blocking the TTR gene from making amyloid protein, which helps prevent further buildup of amyloid in the body.

This medication is specifically approved for treating both nerve involvement (polyneuropathy) and heart symptoms (cardiomyopathy) in people with hATTR amyloidosis. Clinical trials have evaluated both the safety and effectiveness of vutrisiran in patients with hereditary ATTR amyloidosis. The medication is part of a newer generation of treatments that have become available in recent years to help manage the condition.

 AI-generated responses are not a substitute for medical advice. These services are not intended to diagnose, treat, or cure any condition or disease. Always ask your doctor about specific health concerns.

6 Facts To Know About hATTR Amyloidosis

What’s the Life Expectancy With hATTR Amyloidosis?